Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Conditions
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale Cancer Center - Yale New Haven Hospital, New Haven, Connecticut, United States
Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, New York, United States
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Institut Bergonie, Bordeaux, France
Contact: Study coordinator (Principal Investigator) · d.teyssonneau@bordeaux.unicancer.fr · +33 5 56 33 33 33Institut Godinot, Reims, France
Contact: Study coordinator (Principal Investigator) · camille.mazza@reims.unicancer.fr · +33326504111Orszagos Onkologiai Intezet, Budapest, Hungary
Centrum Terapii Wspolczesnej, Lodz, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Poland
START La Rioja, Hospital Universitario San Pedro, Logroño, La Rioja, Spain
Contact: Study coordinator (Principal Investigator) · maria.demiguel@startrioja.com · +34 941 27 87 60Hospital Universitari Vall d'Hebron, Barcelona, Spain
START Barcelona, CIOCC, Hospital Universitario Nou Delfos, Barcelona, Spain
Contact: Study coordinator (Principal Investigator) · tatiana.hernandez@start-barcelona.com · +34 93 254 50 30Hospital Universitario Reina Sofía, Córdoba, Spain
Clinica Universidad de Navarra - Madrid, Madrid, Spain
Hospital 12 de Octubre, Madrid, Spain
START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain
Hospital Universitario Virgen de la Victoria, Málaga, Spain
Universitary Hospital Virgen del Rocio, Seville, Spain
Instituto Valenciano de Oncologia, Valencia, Spain